Multiple-dose, safety, pharmacokinetics, and pharmacodynamics of a new selective estrogen receptor modulator, ERA-923, in healthy postmenopausal women

Journal of Clinical Pharmacology

Volumn 42, Issue 2, 2002, Pages 157-165

  Cotreau, Monette M ^a   Stonis, Lucille ^a   Dykstra, Kevin H ^a   Gandhi, Thimma ^a   Gutierrez, Maria ^c,d   Xu, Jing ^b   Park, Young ^b   Burghart, Peter H ^a   Schwertschlag, Ullrich S ^a  

^a Bioanalytical Research and Development   (United States)

^b Biostatistics and Clinical Information Systems   (United States)

^c PFIZER INC   (United States)

^d ICSL Clinical Studies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PIPENDOXIFENE; PLACEBO; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST METASTASIS; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENTEROHEPATIC CIRCULATION; FEMALE; HEADACHE; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; LIPID DIET; NORMAL HUMAN; PAIN; POSTMENOPAUSE; TRANSVAGINAL ECHOGRAPHY;

AGED; AREA UNDER CURVE; BIOLOGICAL MARKERS; BONE AND BONES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FASTING; FEMALE; HALF-LIFE; HUMANS; INDOLES; LIPIDS; MIDDLE AGED; PIPERIDINES; POSTMENOPAUSE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 0036154579     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700222011193     Document Type: Article

References (23)

1. Crosstalk between the insulin-like growth factors and estrogens in breast cancer
2. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy
3. Molecular biology of the estrogen receptor aids in the understanding of tamoxifen resistance and breast cancer prevention with raloxifene
4. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
5. Symptoms associated with tamoxifen treatment in post-menopausal women
6. Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens
7. Pre-clinical pharmacology profile of a new selective estrogen receptor modulator (SERM), ERA-923, for the treatment of breast cancer
8. Examination of some factors responsible for a food-induced increase in absorption of atovaquone
9. Diet-controlled blood levels of oltipraz in healthy male subjects
10. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole
11. Effects of food on clinical pharmacokinetics
12. Pharmacokinetics and bioavailability of tamoxifen in postmenopausal healthy women
13. Pharmacokinetics of raloxifene and its clinical application
14. Selective estrogen receptor modulators: Clinical spectrum
15. Selective estrogen receptor modulators: Women's panacea for the next millennium
16. Tamoxifen, raloxifene, and the prevention of breast cancer
17. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
18. Effects of tamoxifen and toremifene on urinary excretion of pyridinoline and deoxypyridinoline and bone density in postmenopausal patients with breast cancer
19. Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal women
20. Changes in serum lipid and lipoprotein levels in postmenopausal patients with nodepositive breast cancer treated with tamoxifen
21. Administration of long-term tamoxifen therapy modifies the plasma lipoprotein-lipid concentration and lipid transfer protein I activity in postmenopausal women with breast cancer
22. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial
23. Selective estrogen receptor modulators: An alternative to hormone replacement therapy